Clover Biopharmaceuticals, Ltd. (HKG:2197)

Clover Biopharmaceuticals Statistics

Total Valuation

HKG:2197 has a market cap or net worth of HKD 3.71 billion. The enterprise value is 3.41 billion.

Market Cap	3.71B
Enterprise Value	3.41B

Important Dates

The last earnings date was Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

HKG:2197 has 1.30 billion shares outstanding. The number of shares has increased by 0.53% in one year.

Current Share Class	1.30B
Shares Outstanding	1.30B
Shares Change (YoY)	+0.53%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	20.67%
Owned by Institutions (%)	9.29%
Float	802.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	951.80
PB Ratio	-1.86
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.94
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.73

Financial Position

The company has a current ratio of 0.19

Current Ratio	0.19
Quick Ratio	0.17
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-676.10

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-25.07%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	19.72%
Weighted Average Cost of Capital (WACC)	18.56%
Revenue Per Employee	15,177
Profits Per Employee	-888,049
Employee Count	257
Asset Turnover	0.01
Inventory Turnover	0.02

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1,226.92% in the last 52 weeks. The beta is 2.61, so HKG:2197's price volatility has been higher than the market average.

Beta (5Y)	2.61
52-Week Price Change	+1,226.92%
50-Day Moving Average	2.55
200-Day Moving Average	2.11
Relative Strength Index (RSI)	45.84
Average Volume (20 Days)	4,190,520

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HKG:2197 had revenue of HKD 3.90 million and -228.23 million in losses. Loss per share was -0.18.

Revenue	3.90M
Gross Profit	3.68M
Operating Income	-283.64M
Pretax Income	-228.23M
Net Income	-228.23M
EBITDA	-264.65M
EBIT	-283.64M
Loss Per Share	-0.18

Balance Sheet

The company has 314.09 million in cash and 11.81 million in debt, with a net cash position of 302.28 million or 0.23 per share.

Cash & Cash Equivalents	314.09M
Total Debt	11.81M
Net Cash	302.28M
Net Cash Per Share	0.23
Equity (Book Value)	-2.00B
Book Value Per Share	-1.54
Working Capital	-1.57B

Cash Flow

In the last 12 months, operating cash flow was -216.80 million and capital expenditures -36,723, giving a free cash flow of -216.84 million.

Operating Cash Flow	-216.80M
Capital Expenditures	-36,723
Depreciation & Amortization	19.63M
Net Borrowing	-90.99M
Free Cash Flow	-216.84M
FCF Per Share	-0.17

Margins

Gross Margin	94.29%
Operating Margin	-7,272.18%
Pretax Margin	-5,851.41%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HKG:2197 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.53%
Shareholder Yield	-0.53%
Earnings Yield	-6.15%
FCF Yield	-5.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HKG:2197 has an Altman Z-Score of -38.08 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-38.08
Piotroski F-Score	2